Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Amortization - IntangiblesConsolidated Net IncomeCost of RevenueEBITEBITDAEBTEPS (Basic)Gross ProfitIncome from Continuing OperationsIncome towards Parent CompanyInterest & Investment IncomeNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeOther Non Operating IncomeOther Operating ExpensesProfit After TaxResearch & DevelopmentRestructuring CostsRevenueSelling, General & AdministrativeTax ProvisionsTax Rate
Others
Ratios

Harvard Bioscience (HBIO) Other Non Operating Income (2016 - 2025)

Historic Other Non Operating Income for Harvard Bioscience (HBIO) over the last 17 years, with Q3 2025 value amounting to -$365000.0.

  • Harvard Bioscience's Other Non Operating Income rose 2953.67% to -$365000.0 in Q3 2025 from the same period last year, while for Sep 2025 it was -$1.1 million, marking a year-over-year increase of 247.23%. This contributed to the annual value of -$652000.0 for FY2024, which is 18722.47% down from last year.
  • Per Harvard Bioscience's latest filing, its Other Non Operating Income stood at -$365000.0 for Q3 2025, which was up 2953.67% from -$644000.0 recorded in Q2 2025.
  • Harvard Bioscience's Other Non Operating Income's 5-year high stood at $465000.0 during Q4 2022, with a 5-year trough of -$644000.0 in Q2 2025.
  • Over the past 5 years, Harvard Bioscience's median Other Non Operating Income value was -$179000.0 (recorded in 2022), while the average stood at -$135578.9.
  • Its Other Non Operating Income has fluctuated over the past 5 years, first surged by 45384.62% in 2023, then plummeted by 125111.11% in 2024.
  • Quarter analysis of 5 years shows Harvard Bioscience's Other Non Operating Income stood at -$189000.0 in 2021, then soared by 346.03% to $465000.0 in 2022, then plummeted by 171.4% to -$332000.0 in 2023, then skyrocketed by 156.93% to $189000.0 in 2024, then crashed by 293.12% to -$365000.0 in 2025.
  • Its Other Non Operating Income stands at -$365000.0 for Q3 2025, versus -$644000.0 for Q2 2025 and -$324000.0 for Q1 2025.